Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;27(10):3971-3972.
doi: 10.1245/s10434-020-08495-6. Epub 2020 Apr 27.

ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy

Talia Golan  1   2 , Alex Barenboim  2   3 , Nir Lubezky  4   5
Affiliations

ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy

Talia Golan et al. Ann Surg Oncol. 2020 Oct.
No abstract available

PubMed Disclaimer

References

    1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406. - DOI
    1. Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol. 2018;44:1619–1623. - DOI
    1. Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782–794. - DOI
    1. Golan T, Barenboim A, Lahat G, et al. Increased rate of complete pathological response following neoadjuvant FOLFIRINOX in BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08469-8 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources